StageZero Life Sciences Ltd. (OTCMKTS:SZLSF – Get Rating) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 30,000 shares, an increase of 934.5% from the February 28th total of 2,900 shares. Based on an average daily trading volume, of 9,100 shares, the short-interest ratio is presently 3.3 days.

StageZero Life Sciences Stock Performance

Shares of SZLSF stock remained flat at $0.08 during trading on Monday. The company had a trading volume of 200 shares, compared to its average volume of 11,114. The company has a quick ratio of 0.04, a current ratio of 0.08 and a debt-to-equity ratio of 0.44. The company has a market cap of $8.23 million, a price-to-earnings ratio of -1.11 and a beta of 0.63. The stock's 50 day simple moving average is $0.07 and its 200-day simple moving average is $0.06. StageZero Life Sciences has a fifty-two week low of $0.04 and a fifty-two week high of $0.15.

About StageZero Life Sciences

(Get Rating)

StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K.

Featured Stories

• Get a free copy of the StockNews.com research report on StageZero Life Sciences (SZLSF)
• 3 High Yields On Breakout Watch With Analyst Tailwinds
• Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
• 3 Financials The Insiders Are Buying
• Can Carnival Cruise Lines Set Sail For New Highs?
• If Safety is Your Concern, Then Take a Look at Sandy Spring Bank

Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.